Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill Fiedler-Kelly

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pharmacology|March 26, 2009
Kerfuffle!Thaddeus H Grasela, Elizabeth Ludwig, Jill Fiedler-Kelly
Journal of Clinical Pharmacology|July 21, 2016
Population Pharmacokinetic Modeling of Armodafinil and Its Major MetabolitesSusan Willavize, Jill Fiedler-Kelly, Elizabeth Ludwig, et al.
Pharmaceutics|June 2, 2021
Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY<sup>®</sup>) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 StudyAksana Jones, Orit Cohen-Barak, Andrijana Radivojevic, et al.
Journal of Clinical Pharmacology|December 3, 2022
Immunogenicity Considerations for Therapeutic Modalities Used in Rare DiseasesAnas M Fathallah, Philip Oldfield, Jill Fiedler-Kelly, et al.
Plos One|July 11, 2013
A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on DialysisHimanshu Naik, Max C Tsai, Jill Fiedler-Kelly, et al.
Headache|May 24, 2020
Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy ResponsesJill Fiedler-Kelly, Julie Passarell, Elizabeth Ludwig, et al.
The AAPS Journal|June 11, 2014
Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrationsSébastien Bihorel, Jill Fiedler-Kelly, Elizabeth Ludwig, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 28, 2018
Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizuresSoujanya Sunkaraneni, Elizabeth Ludwig, Jill Fiedler-Kelly, et al.
Clinical Pharmacology and Therapeutics|April 7, 2023
Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress-Testing Renal Function Range in Real World PatientsJ Robert Powell, Farah Al Qaraghuli, Jill Fiedler-Kelly, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|March 21, 2014
A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimensMona Darwish, Mary Bond, Nancy Ricciotti, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|March 26, 2009
Kerfuffle!Thaddeus H Grasela, Elizabeth Ludwig, Jill Fiedler-Kelly
Journal of Clinical Pharmacology|July 21, 2016
Population Pharmacokinetic Modeling of Armodafinil and Its Major MetabolitesSusan Willavize, Jill Fiedler-Kelly, Elizabeth Ludwig, et al.
Pharmaceutics|June 2, 2021
Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY<sup>®</sup>) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 StudyAksana Jones, Orit Cohen-Barak, Andrijana Radivojevic, et al.
Journal of Clinical Pharmacology|December 3, 2022
Immunogenicity Considerations for Therapeutic Modalities Used in Rare DiseasesAnas M Fathallah, Philip Oldfield, Jill Fiedler-Kelly, et al.
Plos One|July 11, 2013
A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on DialysisHimanshu Naik, Max C Tsai, Jill Fiedler-Kelly, et al.
Headache|May 24, 2020
Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy ResponsesJill Fiedler-Kelly, Julie Passarell, Elizabeth Ludwig, et al.
The AAPS Journal|June 11, 2014
Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrationsSébastien Bihorel, Jill Fiedler-Kelly, Elizabeth Ludwig, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 28, 2018
Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizuresSoujanya Sunkaraneni, Elizabeth Ludwig, Jill Fiedler-Kelly, et al.
Clinical Pharmacology and Therapeutics|April 7, 2023
Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress-Testing Renal Function Range in Real World PatientsJ Robert Powell, Farah Al Qaraghuli, Jill Fiedler-Kelly, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|March 21, 2014
A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimensMona Darwish, Mary Bond, Nancy Ricciotti, et al.
Pageof 3